Clinical Trials Browser

INDUSTRY × Expanded_access × ripretinib × Clear all

NCT04148092 2020-05-29

Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST

Approved for marketing

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors